Joshi, Shashank
Jayanth, Vathsala
Loganathan, Subramanian http://orcid.org/0000-0001-7186-0049
Sambandamurthy, Vasan K.
Athalye, Sandeep N.
Funding for this research was provided by:
Biocon
Article History
Accepted: 24 July 2023
First Online: 14 August 2023
Declarations
:
: Shashank Joshi has received Speaker/Advisory/Research Grants from Abbott, Alkem, Astra Zeneca, Bayer, Biocon, Boehringer Ingelheim, Eli Lilly, Franco Indian, Glenmark, Lupin, Marico, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Serdia, Torrent Pharma, Twin Health and Zydus. Sandeep N. Athalye, Subramanian Loganathan, and Vathsala Jayanth are currently employed with Biocon Biologics Ltd and Vasan K. Sambandamurthy is previous employee of Biocon Limited.
: Biocon Limited.
: S.N.A, S.L, V.J, and V.K.S. hold stocks in Biocon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or financial conflict with the subject matter or materials discussed in the review apart from those disclosed. For S.J., please refer to ‘Disclosures’.
: The data supporting the study findings are available from the corresponding author, Subramanian Loganathan, upon reasonable request.
: The ethical standards of independent ethics committees or institutional review board were followed during the conduct of the clinical trials included in this review.
: All the subjects involved in the clinical trials mentioned in this review received informed consent prior to the study-related procedures, which was duly signed by the subjects and the investigators.
: Not applicable.
: Not applicable.
: S.J., V.J., S.L., V.K.S., and S.N.A. designed and conceptualized the review article. All the authors were involved in writing, reviewing and approving the manuscript. As the guarantor of this work, S.L., takes full responsibility for the work, including the decision to submit and publish the manuscript.